Michael Zile to Cardiovascular Diseases
This is a "connection" page, showing publications Michael Zile has written about Cardiovascular Diseases.
Connection Strength
0.469
-
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 10 24; 381(17):1609-1620.
Score: 0.100
-
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 06; 7(6):457-465.
Score: 0.097
-
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019 May; 21(5):577-587.
Score: 0.095
-
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct; 10(10).
Score: 0.087
-
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2019 05; 7(5):418-427.
Score: 0.024
-
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017 Feb 21; 135(8):724-735.
Score: 0.021
-
Efficacy of Sacubitril/Valsartan Relative to?a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail. 2016 10; 4(10):816-822.
Score: 0.020
-
Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011 May; 4(3):324-31.
Score: 0.014
-
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 04; 359(23):2456-67.
Score: 0.012